Occlusion and Reperfusion-Induced Arrhythmias in Rats
- 1 May 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 15 (5) , 816-825
- https://doi.org/10.1097/00005344-199005000-00018
Abstract
The role of blood platelets in ischemia- and reperfusion-induced arrhythmias and the efficacy of three calcium blocking drugs (verapamil, diltiazem, and nicardipine) in preventing the arrhythmias were investigated. Using anesthetized rats, we measured platelet count (Pc) continuously in vivo with a Technicon autocounter. Thromboxane B2 (TxB2) and 6-keto-PGF1.alpha. levels in blood from coronary sinus were determined by radioimmunassay (RIA). Myocardial ischemia and arrhythmias were monitored from lead I ECG during and after occlusion of the left anterior descending coronary artery (LAD) for 7 min. Ischemia-induced arrhythmias were mainly ventricular ectopic contractions (VECs), whereas reperfusion produced VECs, ventricular tachycardia (VT), and reversible and irreversible ventricular fibrillation (VF). Both ischemia and reperfusion decreased platelet count and increased TxB2 level in blood from the coronary sinus. The effects of the CEBs were determined at two dose levels (0.1 and 0.3 mg/kg). Each calcium entry blocker (CEB), at both dose levels, significantly inhibited ischemia-induced arrhythmias. Verapamil and diltiazem sigificantly reduced reperfusion-induced VECs, prevented VT and irreversible VF, and reduced the number of animals with reversible VF. Nicardipine in preventing arrhythmias was not very effective at either dose. The CEBs also inhibited both ischemia- and reperfusion induced decreases in PC with a moderate increase (up to 7%) as compared with levels in sham-operated controls. The CEBs also significantly reduced TxB2 levels in blood from the coronary sinus. These results indicate that ischemia and postischemic reperfusion both induce platelet aggregation in rats. Aggregation platelets release biologically active substances including thromboxane A2 (TxA2) which exacerbates existing ischemia and facilitates generation of arrhythmias. CEBs inhibit platelet aggregation and TxA2 release and enhance PGI2 synthesis, thereby preventing arrhythmias.This publication has 24 references indexed in Scilit:
- Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmiasNature, 1981
- Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart.Circulation Research, 1980
- Prevention of infarction-induced decrease in circulating platelet count by prostacyclinThrombosis Research, 1980
- Myocardial extracellular K+ and H+ increase and noradrenaline release as possible cause of early arrhythmias following acute coronary artery occlusion in pigsJournal of Molecular and Cellular Cardiology, 1980
- Preservation of ischemic myocardium by pinane thromboxane A2American Journal of Physiology-Heart and Circulatory Physiology, 1980
- ELEVATION OF PLATELET FACTOR 4 IN ACUTE MYOCARDIAL-INFARCTION - MEASUREMENT BY RADIOIMMUNOASSAY1978
- EXPERIMENTAL MYOCARDIAL-INFARCTION IN RAT - QUALITATIVE AND QUANTITATIVE CHANGES DURING PATHOLOGIC EVOLUTION1978
- The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs.Circulation, 1977
- The regulation of the calcium conductance of cardiac muscle by adrenaline.The Journal of Physiology, 1977
- Platelet aggregation in partially obstructed vessels and its elimination with aspirin.Circulation, 1976